|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | Bolus infusion 3 mcg | Bolus infusion\*0.3 mcg | Subcutaneous injection 2 mcg/kg/day | Continuous intravenous infusion2 mcg/kg/day | SubcutaneousALT-803T (2)10 mcg/kg |
| Cmax pg/kg | 43,900 | 1,260 | 1,638 |  5,662 | 8,000 |
| pg/mL AUC | 43,400 | 1,960 |  | 321,747 |  |
| Maximum fold increase in IL-6concentration pg/mL | 30 | NA | 17 | 10 |  |
| MTD | 0.3 mcg/kg | 0.3 mcg/kg | 2 mcg/kg | 2 mcg/kg |  |
| Maximum fold increase in numberof circulating NK cells | ≥10 | 3 |  10.8 | 38 | 8 |

\*MTD or expansion cohort

**Supplementary Table 2: Comparison of Pharmacokinetics with Different Dosing Strategies**